Eidos Therapeutics Inc (NASDAQ:EIDX) major shareholder Bridgebio Pharma, Inc. bought 882,353 shares of the stock in a transaction dated Wednesday, July 3rd. The stock was bought at an average price of $29.90 per share, with a total value of $26,382,354.70. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Bridgebio Pharma, Inc. also recently made the following trade(s):
- On Friday, May 24th, Bridgebio Pharma, Inc. bought 1,103,848 shares of Eidos Therapeutics stock. The stock was bought at an average price of $25.93 per share, with a total value of $28,622,778.64.
Shares of NASDAQ EIDX opened at $39.17 on Wednesday. Eidos Therapeutics Inc has a fifty-two week low of $8.89 and a fifty-two week high of $39.95. The company’s 50 day simple moving average is $30.92. The company has a current ratio of 19.04, a quick ratio of 19.04 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.35 billion and a price-to-earnings ratio of -21.06.
Hedge funds and other institutional investors have recently modified their holdings of the business. New York State Common Retirement Fund acquired a new stake in Eidos Therapeutics during the 4th quarter valued at approximately $69,000. BNP Paribas Arbitrage SA acquired a new stake in Eidos Therapeutics during the 1st quarter valued at approximately $80,000. Metropolitan Life Insurance Co NY acquired a new stake in Eidos Therapeutics during the 1st quarter valued at approximately $143,000. MetLife Investment Advisors LLC acquired a new stake in Eidos Therapeutics during the 1st quarter valued at approximately $198,000. Finally, Fiduciary Trust Co. acquired a new stake in Eidos Therapeutics during the 1st quarter valued at approximately $211,000. Hedge funds and other institutional investors own 34.01% of the company’s stock.
EIDX has been the subject of a number of recent research reports. Zacks Investment Research lowered Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. BTIG Research initiated coverage on Eidos Therapeutics in a research note on Wednesday, April 17th. They issued a “buy” rating and a $38.00 target price for the company. Finally, BMO Capital Markets increased their target price on Eidos Therapeutics from $28.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, May 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Eidos Therapeutics has an average rating of “Buy” and a consensus target price of $30.29.
Eidos Therapeutics Company Profile
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Recommended Story: How to identify percentage decliners
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.